DMYD B Stock Overview
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Diamyd Medical AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr11.18 |
| 52 Week High | kr21.50 |
| 52 Week Low | kr6.41 |
| Beta | 2.07 |
| 1 Month Change | 3.52% |
| 3 Month Change | 37.18% |
| 1 Year Change | -41.03% |
| 3 Year Change | -58.41% |
| 5 Year Change | 55.93% |
| Change since IPO | 149.55% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Diamyd Medical's (STO:DMYD B) Cash Burn Rate
Feb 02
We Think Diamyd Medical (STO:DMYD B) Needs To Drive Business Growth Carefully
Sep 22What You Need To Know About Diamyd Medical AB (publ)'s (STO:DMYD B) Investor Composition
Jan 22Here's Why Diamyd Medical's (STO:DMYD B) Statutory Earnings Are Arguably Too Conservative
Nov 30Shareholder Returns
| DMYD B | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 14.0% | -0.06% | 0.9% |
| 1Y | -41.0% | -5.3% | 10.3% |
Return vs Industry: DMYD B underperformed the Swedish Biotechs industry which returned -4.3% over the past year.
Return vs Market: DMYD B underperformed the Swedish Market which returned 10.7% over the past year.
Price Volatility
| DMYD B volatility | |
|---|---|
| DMYD B Average Weekly Movement | 15.6% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: DMYD B's share price has been volatile over the past 3 months.
Volatility Over Time: DMYD B's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 26 | Ulf Hannelius | www.diamyd.com |
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in type 1 diabetes.
Diamyd Medical AB (publ) Fundamentals Summary
| DMYD B fundamental statistics | |
|---|---|
| Market cap | kr1.15b |
| Earnings (TTM) | -kr120.18m |
| Revenue (TTM) | kr282.00k |
4,068x
P/S Ratio-9.5x
P/E RatioIs DMYD B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMYD B income statement (TTM) | |
|---|---|
| Revenue | kr282.00k |
| Cost of Revenue | kr3.76m |
| Gross Profit | -kr3.48m |
| Other Expenses | kr116.70m |
| Earnings | -kr120.18m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
Jun 26, 2024
| Earnings per share (EPS) | -1.17 |
| Gross Margin | -1,234.75% |
| Net Profit Margin | -42,617.73% |
| Debt/Equity Ratio | 0% |
How did DMYD B perform over the long term?
See historical performance and comparison